BioSpace News Archive

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics’ European Patent Application No.19805439.7 titled, “Methods for Treating Alzheimer’s Disease.”

June 12, 2023
·
3 min read
BioForest

Many long COVID patients suffer from persistent inflammation, study finds

An overactive inflammatory response could be at the root of many long COVID cases, according to a new study from the Allen Institute and Fred Hutchinson Cancer Center.

June 12, 2023
·
5 min read
Lone Star Bio

New Publication Highlights Basic Science Supporting Simufilam

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal.

June 12, 2023
·
5 min read
Drug Development

Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion

Skye completes dosing of final cohort of healthy volunteers in study of first-and-only-in-class proprietary cannabinoid derivative

June 12, 2023
·
4 min read
Drug Development

Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema .

June 12, 2023
·
5 min read
Business

Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations

Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment.

June 12, 2023
·
2 min read
Policy

Indivior to Commence Trading on Nasdaq

Indivior PLC announces that the U.S. Securities & Exchange Commission declared its registration statement on Form 20-F effective on June 9.

June 12, 2023
·
6 min read